Vericel Advances Use of Cell Therapies

episode

Vanguards of Healthcare by Bloomberg Intelligence not yet transcribed

▲ 0

Transcript

This episode hasn't been transcribed yet Upvotes decide what gets transcribed next — 0 so far. Sign in to upvote

More from Vanguards of Healthcare by Bloomberg Intelligence

Athenahealth's Strategic Reset, Push for Speed in Ambulatory Care 53 min · 02 Apr 2026

Inside Insilico Medicine’s AI Strategy and Lilly Breakthrough 1h 2m · 31 Mar 2026

Abridge Moving AI From Scribing to Clinical Workflows 54 min · 26 Mar 2026

7Wire's Jaffee on the Hard Truths Behind Health-Tech Investing 44 min · 19 Mar 2026

Xaira’s War on Trial-and-Error Drug Development 56 min · 12 Mar 2026

AVS’ Toland on Next Lithotripsy Launch 43 min · 05 Mar 2026

All episodes from Vanguards of Healthcare by Bloomberg Intelligence →

Report any issue

Source

Recorded10 May 2024

Publisheromnycontent.com ↗

Handlerec:13806595

Show notes

Vericel acquired a hidden gem in cartilage repair that other companies had written off, and developed it into a high-growth product that could potentially address a $4 billion market. In this episode of the Vanguards of Health Care podcast, Vericel CEO Nick Colangelo sits down with Matt Henriksson, Bloomberg Intelligence analyst, to talk about how MACI took over as the market leader for cartilage repair in the knee and its potential to do so for the ankle. Colangelo also discusses why the company built a diversified portfolio and how NexoBrid complements its Epicel platform to fill out the company’s burn-care offerings.See omnystudio.com/listener for privacy information.

Ask this episode

“What did the council decide on item 42?” — answered with the speaker and the moment.

Sign in